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Abstract Latinos in the United States are an ethnically
diverse group disproportionately affected by HIV/AIDS.
We describe HIV seroprevalence, HIV risk behaviors and
utilization of health services among Mexican American
injection drug users (IDUs) in California (n = 286) and
compare them to White (n = 830) and African American
(n = 314) IDUs. Study participants were recruited from
syringe exchange programs (n = 24) in California. HIV
seroprevalence among Mexican Americans (0.5%) was
dramatically lower than Whites (5%) and African Ameri-
cans (8%). Mexican Americans reported fewer sex-related
risks than Whites and African Americans though injection-
related risks remained high. Compared to Whites, Mexican
Americans were more likely to participate in drug treat-
ment during a 6 month period (AOR 1.5, 95% CI 1.1, 2.0)
but less likely to receive any health care (AOR 0.6, 95% CI
0.5, 0.8). Exploring cultural and structural factors among
Mexican American IDUs may offer new insights into how
to maintain low rates of HIV seroprevalence and reduce
barriers to health care utilization.
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Introduction
Latinos in the United States (US) are disproportionately
affected by the HIV/AIDS epidemic [1]. The prevention
response to the epidemic among Latinos is complicated by
the cultural, social, and geographic heterogeneity found
within this diverse community [2, 3]. Recent data suggest
an increasing trend in HIV incidence among Latinos in
California, of which Mexicans and Mexican Americans
make up the largest ethnic group (83% in 2007) [4, 5]. As
of December 2007, Latinos in California accounted for
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28% of total HIV cases and 36% of the total population
compared to 24% of HIV cases and 35% of the population
in 2004. Among all HIV tests administered at publicly
funded sites in California in 2003, African American males
had the highest infection rate at 2.74% followed by Latino
males at 2.22% [6]. Men who have sex with men is already
well established as a behavioral risk for HIV among Lati-
nos in California [7, 8], though it is less clear how the dual
risks of injection drug use (IDU) and men who have with
men (MSM) are present among Latino, specifically Mexi-
cans and Mexican–Americans, IDUs. Recent epidemio-
logical data from public testing sites also suggest that HIV
positivity in California is highest among Latino MSM who
also inject drugs (5.2%) [9].
Previous studies have identified Puerto Rican IDUs as a
high risk Latino subgroup [10]. In 2002, 45% of Puerto
Rican IDUs in New York City were infected with HIV
along with 44% of Black IDUs and 32% of White IDUs
[11]. Among Puerto Rican IDUs, access to sterile syringes
[12], incarceration [13], residential status [14], drug scene
roles [15], and sexual identity [16] have been previously
identified as important factors that influence HIV trans-
mission. Comparatively, Mexican Americans have been
shown to have higher rates of drug injection and lower
rates of sharing injection paraphernalia than Puerto Ricans
[17, 18]. In addition to injection risk behavior, data from a
national sample of IDUs suggested that Mexicans and
Mexican Americans engage in less sexual risk behavior
compared to Puerto Ricans [19].
Much of the current HIV prevention research on Mex-
icans or Mexican Americans in California focuses on the
experiences of migrant workers and their needs as an
economically impoverished and highly mobile population
[20–24]. Although the seroprevalence of HIV is very low
in Mexico overall (0.3%), the HIV seroprevalence among a
sample of IDUs in the border cities of Tijuana and Ciudad
Juarez was found to be 1.9% and 4.1%, respectively, in
2005 [22, 25]. Geographic clusters of high HIV seroprev-
alence, injection and sexual risk in border communities
have potential implications for the HIV epidemic in Cali-
fornia. Previous studies have identified acculturation as a
contributing factor to increased drug use and sexual
behavior [23, 26] though conflicting evidence exists for
injection related HIV risk [27, 28]. Research suggests that
mental health issues, changes in gender roles, increased
access to alcohol and drugs, immigration dynamics and
mobility, and reduced perceptions of HIV/AIDS risk can
impact the vulnerability of immigrant Latino groups to
HIV/AIDS [29]. Among a sample of migrant and margin-
ally housed Latinos in California, injection drug use was
reported by almost 30% of the sample that occurred among
Mexican migrants due to the injection of illicit drugs and
lay therapeutic injections of vitamins and medicines [30].
In addition to HIV risk behaviors, the utilization of health
services, including drug treatment programs and frequencies
of visits to services providers such as doctors and hospitals, is
an important component of HIV prevention for IDUs. IDUs
who use drug treatment programs typically reduce their risk
for HIV infection [31, 32]. Research suggests that Latinos are
in greater need of access to drug treatment programs than
African Americans and Whites [33, 34]. Furthermore, a
national survey showed that among those with perceived
need, Latinos were more likely to have less care than needed
or delayed care (22.7% versus 10.7%) for alcoholism, drug
abuse or mental health, compared to Whites [35]. Consis-
tently documented disparities that show reduced access to
health services among Latinos compared to Whites also raise
important concerns for the health status of HIV-positive
Latinos [36–40]. Over the past 10 years, Latinos have
accounted for the largest increase in the number of persons
living with AIDS in California [9].
Using data from the California Syringe Exchange Pro-
gram Study (CalSEP), we described HIV seroprevalence,
HIV risk behaviors and utilization of health services among
a geographically diverse sample of IDUs recruited from all
syringe exchange programs (SEPs) in the state of Califor-
nia between 2001 and 2003. Understanding the context of
HIV risk among Mexican American IDUs will contribute
to our understanding of the prevention needs of a high risk
yet health-seeking group of Latinos in California, and how
these needs may differ from Whites and African Ameri-
cans. Understanding the context of HIV risk among Mex-
ican American IDUs will contribute to the literature on
how and why their HIV prevention needs may differ from
whites and African Americans.
Methods
Participants
The CalSEP study sampled clients from all 24 SEPs in
operation during the study period. The SEPs were located
in 16 California counties. A cross-section of SEP clients
was sampled from each of the SEPs annually from 2001 to
2003. Each SEP was sampled in three consecutive annual
samples, with the exception of two counties which were
only sampled twice.
SEP clients were approached at sites by research staff
and were eligible for study participation if they reported
injecting drugs in the past 30 days. Due to the illegal status
of several SEPs in our sampling frame as well as limited
SEP hours and negative prior experience with research
studies that attempted to randomize eligible study partici-
pants at their program, SEPs and the research team decided
to use convenience sampling.
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The standardized interview elicited information about
demographics, socioeconomic status, drug use history and
practices, access to health care and drug treatment, and
HIV-related risk behaviors such as sharing of injection
paraphernalia and sexual behaviors. Answers were entered
by interviewers into Questionnaire Development System
(QDS) software program (QDS, NOVA Research Inc.,
Bethesda, MD) on lap-top computers to reduce the likeli-
hood of data entry errors by coordinating skip patterns and
running consistency and validity checks. After the inter-
view, each participant received HIV risk reduction coun-
seling, an oral HIV test and referrals to social and medical
services specific to the county where the research was
being conducted. Each participant was paid $10 for par-
ticipating in the study. HIV test results and follow-up
counseling were scheduled for one to 2 weeks later in the




To ascertain information about race/ethnicity, participants
were asked the following question by an interviewer:
‘‘What do you consider to be your primary race or eth-
nicity?’’ and were offered eight distinct categories from
which to choose an answer. If participants chose Latino, a
subsequent question was asked to determine if they were
(1) Mexican American/Chicano, (2) Mexican, (3) Puerto
Rican, (4) Cuban, (5) Central or South American, (6)
Dominican Republic or (7) Other. Of all study participants
in CalSEP (N = 1,588), 317 (20%) self-identified as
Latino. About 87% of the Latino IDUs (n = 286) specified
their ethnicity to be Mexican American (n = 235) or
Mexican (n = 51). The remaining 13% (n = 30) of those
who identified as Latino include individuals of Puerto
Rican, Central or South American, Cuban or Dominican
Republican origin. After excluding the non-Mexican Lati-
nos, we were left with a final sub-sample of n = 286. For
the remainder of this paper, we refer to IDUs as Mexican
American if they identified as either Mexican or Mexican
American/Chicano. IDUs who reported that they were
either Non-Hispanic White (n = 830) or African American
(n = 314) are included as comparison groups for a final
sample (N = 1,430).
Individual Level Variables
Measurement of additional individual variables is descri-
bed in Table 1. Syringe coverage was measured by mul-
tiplying the number of syringes retained (syringes they did
not intend to give, sell or trade to someone else) from their
last SEP visit by their monthly SEP visits and dividing this
total by their total drug injections (including intravenous,
subcutaneous and intramuscular) in the last 30 days [41].
The resulting figure was multiplied by 100 to generate a
percentage of syringe coverage for each participant—150%
coverage or more, 100–149%, 50–99%, and less than 50%
coverage [41].
Zip Code Level Variables
Participants were asked to give their zip code of residence
during the interview regardless of their housing status. We
linked zip code level data from the United States Census
2000 to zip codes given by each CalSEP participant as their
place of residence. Of the final sample (N = 1,430), 82%
were included in the zip code level analyses. No significant
differences were identified between the characteristics of
participants with missing zip code data and participants
without missing data. The medians and inter-quartiles
ranges of select zip code level social and economic indi-
cators are compared for Mexican American IDUs, White
IDUs and African American IDUs using the Kruskal–
Wallis test (Table 3).
Outcome Variables
The four outcome variables in this analysis are all dichot-
omous variables that include (1) syringe sharing, (2)
unprotected vaginal or anal sex, (3) utilization of health
care, and (4) utilization of drug treatment. Syringe sharing
was defined as distributive or receptive syringe sharing at
least one time in the past 30 days. Unprotected vaginal or
anal sex is defined as any vaginal sex, penetrative anal sex
or receptive anal sex without a latex condom. Health ser-
vice utilization was measured in two ways: (1) any health
care in the past 6 months and (2) any drug treatment in the
past 6 months. Utilization of drug treatment was defined as
any use (yes/no) of multiple types of treatment modalities
including methadone detoxification, methadone mainte-
nance, non-methadone outpatient treatment, residential
treatment, and 12-step self-help in the past 6 months.
Finally, utilization of health care was defined as any use
(yes/no) in the past 6 months.
Data Analyses
Individual level categorical variables by racial/ethnic group
were compared using Pearson’s Chi-Square test of Asso-
ciation (Table 1). Individual level continuous variables
(age, education, frequency of injections, frequency of SEP
use) by racial/ethnic group were compared using either
one-way analysis of variance (ANOVA) or Kruskal–Wallis
test, depending on the skewness of the frequency
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distribution. Bivariate logistic regression was used to
identify variables significantly associated with both race/
ethnicity (Mexican American, White and African Ameri-
can) and the main outcomes at the P \ .10 level. Signifi-
cant variables were entered as control variables in
multivariate logistic regression models. We hypothesized
that the availability of drug treatment services would differ
significantly by SEP location (n = 23) and sought to adjust
for this potential bias in the multivariate model rather than
explicitly measure its effect on the outcome. To adjust for
these potential biases, we entered 23 dummy variables into
the multivariate logistic regression model. Final models
retained all variables that remained significant at the
P \ .05 level (Table 2).
Results
Based on HIV tests conducted at time of interview, HIV
seroprevalence was 0.7% (2/286) among Mexican
American IDUs, 5% among White IDUs and 8% among
African American IDUs. In spite of this dramatic differ-
ence in HIV seroprevalence by race/ethnicity, the preva-
lence of behaviors related to injection risk among Mexican
American IDUs were similar to White IDUs and signifi-
cantly higher than African American IDU (Table 1). The
prevalence of distributive and receptive syringe sharing
reported by Mexican American IDUs was not significantly
different than White IDUs. However, the prevalence of
syringe reuse, sharing of cookers and rinse water was
significantly higher among Mexican Americans compared
to White IDUs. No significant differences across racial/
ethnic groups were observed for unprotected vaginal or
anal sex, though some interesting differences in sex-related
risks were noted. Compared to both Whites and African
Americans, Mexican American IDUs reported the lowest
6-month prevalence of sex-related risks, including trading
sex for cash or drugs, MSM, and steady sexual partners
who are IDUs. Because race/ethnicity did not remain sig-
nificantly associated with syringe sharing (either










Heavy alcohol use** 53% 35% 30% 46.8
Smoked crack cocaine in past 30 days** 28% 21% 50% 89.5
Injected heroin in past 30 days** 94% 71% 90% 87.3
Injected methamphetamine in past 30 days** 10% 48% 15% 196.4
Median (IQR) injections in past 30 days** 90 (35,122) 65 (28,120) 70 (30,120) 8.7
Median (IQR) use of SEP in past 6 months** 15 (5,24) 12 (4,24) 22 (6,24) 19.4
Syringe coverage (100%?)** 40% 47% 52% 8.7
HIV-related
HIV antibody positive** 0.7% 5% 8% 18.8
Receptive syringe sharing in past 30 days** 23% 26% 12% 26.3
Distributive syringe sharing in past 30 days** 31% 29% 15% 26.6
Reused needles in past 30 days** 68% 48% 56% 26.4
Shared rinse water in past 30 days** 49% 40% 29% 25.0
Shared cooker in past 30 days* 60% 52% 51% 6.8
Unprotected vaginal/anal sex in past 30 days 62% 59% 55% 4.5
Traded sex for cash or drugs in past 6 months* 6% 12% 11% 9.5
Men having sex with men in past 6 months 2% 4% 5% 2.8
Steady IDU sex partner in past 6 months* 25% 38% 30% 19.7
Health-related
History of abscess in past 12 months 48% 41% 40% 6.5
Self-report Hepatitis C positive 53% 53% 48% 1.3
History of drug overdose in past 12 months** 11% 7% 15% 15.7
Received any drug treatment in past 6 months** 41% 31% 28% 13.4
Received any health care in past 6 months** 47% 57% 64% 25.2
* P \ .05; ** P \ .01
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distributive or receptive) or unprotected vaginal or anal sex
in the final model (results not shown), we do not present the
results of our multivariate analysis.
Overall, our sample of Mexican American IDUs had a
median age of 44 years (IQR 35, 50), a median injection
drug use history of 21 years (IQR 9,30) and a 46.9%
prevalence of current homelessness. Regarding socio-
demographic variables, our sub-sample of Mexican
Americans included more men compared to our sub-sam-
ple of Whites (77.6% men compared to 63.6%; v2 = 19.2,
N = 1,106, P \ .01), had fewer mean years of education
than Whites and African Americans (10.7 years, SD = 2.3
compared to 12.2 years, SD = 2.2 and 12 years,
SD = 1.7; F = 54.1, N = 1,419, P \ .01) and reported a
higher prevalence of arrest in the past 6 months than
Whites (23.7% compared to 31.4; v2 = 5.9, N = 1,100,
P = .015) and a lower prevalence of arrest than African
Americans (23.7% compared to 18.8%; not significant).
Table 1 presents drug-related, health-related and HIV-
related individual variables by race/ethnicity. The highest
prevalence of heroin injection and the lowest prevalence of
methamphetamine injection were reported by Mexican
American IDUs. Regardless of drug type, Mexican
American IDUs reported the highest median number of
injections in a 30 day period. Mexican Americans also
reported the heaviest alcohol use in the past 30 days.
Bivariate analyses identified significant differences
between race/ethnicity and use of health services. Recent
use (6 month) of any drug treatment was highest among
Mexican American IDUs compared to White IDUs or
African American IDUs. The association between race/
ethnicity and drug treatment remained statistically signifi-
cant in multivariate analysis (Table 2). Compared to White
IDUs, Mexican American IDUs have higher odds of using
drug treatment in the past 6 months (AOR 1.6, 95% CI 1.1,
2.1). The Hosmer–Lemeshow goodness-of-fit test showed
satisfactory model-data fit (v2(4) = 8.0, P = .1). Con-
versely, Mexican American IDUs reported the lowest
percentage of using health care for any reason (separate
from drug treatment), compared to White or African
American IDUs. Again, the association between race/eth-
nicity and use of any health care remained statistically
significant after controlling for additional individual level
variables (Table 2). Mexican American IDUs had lower
adjusted odds of using any health care in a 6 month period
compared to White IDUs (AOR 0.6, 95% CI 0.5, 0.8). The
Hosmer–Lemeshow goodness-of-fit test showed satisfac-
tory model-data fit (v2(8) = 11.3, P = .19).
We were secondarily interested in reported frequency of
SEP use and levels of syringe coverage (Table 1). Several
significant differences were noted. Though Mexican
American IDUS reported a similar frequency of SEP use
than White IDUs during the past 6 months, Mexican
American IDUs had the lowest levels of 100%? syringe
coverage compared to both Whites and African Americans.
Table 3 presents the median percentages of zip code
level variables by race/ethnicity. Our data suggest that
Mexican American IDUs live in zip codes that have a
majority of Hispanic residents; in comparison, Whites and
African Americans lived in zip codes with significantly
fewer Hispanic residents. The median percentage of
households living under the poverty level was also lower in
zip codes where Mexican American IDUs live than that of
Whites and African Americans, as is the percentage of
female headed households.
Discussion
We present data on HIV risk behaviors and HIV sero-
prevalence among Mexican American, White and African
American IDUs. Similar to recent studies of HIV sero-
prevalence among Mexican IDUs on the US/Mexico border
[21, 22, 25], HIV seroprevalence was extremely low
(0.7%) in our sample. Sexual risks might help explain why
Mexican American IDUs in our sample have such a low
HIV prevalence in spite of having equal levels of syringe
sharing and lower access to sterile syringes than Whites
and African Americans [42, 43]. Reports of trading sex for
cash or drugs (6%) and injection of methamphetamines
(10%) were significantly lower for Mexican Americans
IDUs than Whites and African Americans. Though not
Table 2 Multivariate analysisa of ethnic differences in health ser-




Received any health care in past 6 months
Mexican American** 0.6 (0.5,0.8)
White Referent
African American 0.73 (0.50,0.99)
Male** 0.64 (0.50,0.82)
History of abscess in past 12 months** 1.96 (1.6,2.5)
History of drug overdose in past 12 months** 1.7 (1.2,2.4)
Years of education** 1.1 (1.1,1.2)
HIV antibody status** 3.1 (1.6,6.0)
Received drug treatment in past 6 months
Mexican American** 1.5 (1.1, 2.0)
White Referent
African American 0.84 (0.6,1.1)
History of abscess in past 12 months** 1.5 (1.2,1.9)
a Adjusted odds ratios were estimated using multivariate logistic
regression
* P \ .05; ** P \ .01
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statistically significant, Mexican American IDUs in our
sample reported the smallest prevalence of men having sex
with other men (2%). It is plausible to suggest that HIV has
remained low among our sample of Mexican American
IDUs because it is being transmitted primarily among
subpopulations with a high prevalence of sexual risk
behaviors such as MSM.
Syringe coverage for Mexican Americans, or the per-
centage of one shot for one syringe coverage, was signifi-
cantly lower than coverage for Whites and African–
Americans (Table 1). Individual syringe coverage has been
strongly associated with safer injection behaviors, includ-
ing lower odds of syringe sharing [41]. The high preva-
lence of abscess, overdose and Hepatitis C among Mexican
American IDUs suggests that injection risk behaviors,
although not resulting in a high HIV seroprevalence, are
detrimental to the health status of this population. These
findings, coupled with the high frequency of total injections
and low levels of 100? syringe coverage, make it impor-
tant to further study injection-related risks of Mexican
American IDUs.
Our data suggest that Mexican American IDUs are at
risk for injection-related non-HIV related health outcomes,
and given the higher reported use of drug treatment, we
emphasize the incorporation or strengthening of prevention
efforts to reduce abscesses, overdose and Hepatitis C at
drug treatment facilities. Previous studies have convinc-
ingly demonstrated that methadone treatment is an effec-
tive way to prevent HIV [44–47], though it is more likely
that a lack of sexual risk accounted for the dramatically
low seroprevalence observed in our sample of Mexican
American IDUs. Regardless, linkages with prevention
services such as drug treatment represent the opportunity to
reinforce prevention of sex-related HIV risk and expand
prevention efforts for injection-related non-HIV health
risks. It is unclear why Mexican Americans are accessing
drug treatment programs in greater numbers than Whites
and African Americans. Referrals from SEPs, cultural
differences in responding to drug use and abuse, or geo-
graphic availability of treatment services may explain the
observed differences [48]. Structural factors such as
neighborhood dynamics and composition, including social
norms and economic disadvantage may also contribute to
access and utilization of drug treatment programs. Our zip
code level census data suggests that Mexican American
IDUs reside in ethnically homogenous communities and
warrants a more detailed analysis of HIV prevention ser-
vices available in Latino neighborhoods. A recent study in
Los Angeles found that racial differences in treatment
completion were related to differences in levels of neigh-
borhood disadvantage [49]. Our geographic data also
showed that zip codes where Mexican American IDUs
reside had a lower percentage of residents living under the
poverty level than zip codes where White and African
American IDUs reside.
The higher odds of using drug treatment in the past
6 months are contrasted with the lower odds of using any
health care in the past 6 months regardless of job status,
education, income level, and past medical histories of
abscess and overdose. Overall, our data is consistent with
research in the United States and California that shows
Latinos are less likely to utilize health care [38, 40]. Our
participants overwhelmingly chose to conduct their inter-
views in English (99%) which makes it unlikely that our
participants would experience language barriers to
accessing health care as is often reported in the literature
[50]. However, we did not assess the immigration status or
geographic mobility of our participants. No significant
differences in socio-demographics were noted between our
participants who identified as Mexican compared to those
who identified as Mexican American. It is possible that
perceived issues of documentation might negatively impact
Table 3 Zip code level characteristics of IDUs by ethnicity, CalSEP study, 2001–2003
Census 2000 variables Mexican American
(N = 238) (%)
White (N = 649) (%) African American
(N = 287) (%)
Kruskal–Wallis
test statistica
Median ‘Hispanic’ ethnicity** 51.8 21.9 29.1 199.6
Median households below poverty level** 14.7 23.6 19.4 134.8
Median households on public assistance** 7.3 3.9 9.6 52.9
Median unemployed males in labor force** 8.6 6.5 11.3 136.2
Median vacant housing 14.4 13.0 12.9 49.7
Median housing occupied by renters** 54.1 52.3 60.3 30.3
Median female headed households** 3.9 8.2 6.6 159.9
Median households in same house as 1995 51 48 50 18.1
a Degrees of freedom equal two for all statistical tests
** P \ .01
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utilization of health care in a way that is not experienced
when accessing drug treatment programs. Our study par-
ticipants may not have access to culturally competent
health care services that also address their stigmatized
identities as IDUs. Because Latinos with HIV/AIDS in
California are at risk for poor health outcomes compared
with Whites [51], determining barriers to care in high risk
groups such as our study population carries significant
implications if HIV incidence begins to increase. Improv-
ing linkages with health care providers might also be cru-
cial for those in need of specialized care related to drug-
related conditions such as Hepatitis C, endocarditis,
abscesses and overdoses.
Study Limitations
There are several limitations in study design that should be
considered when interpreting the results of this study. The
CalSEP study was not designed to specifically recruit or
study IDUs of Mexican descent. Thus we are not able to
study many relevant variables that might explain our
findings and differences between ethnic groups. Our study
is cross-sectional in design and therefore we cannot assess
causal relationships between predictors and outcomes.
Social desirability might have differentially impacted the
self-report of behaviors across ethnic groups. Selection of
our study participants at SEPs limits our findings to IDUs
already accessing community-based HIV prevention ser-
vices. It is also possible that illegal immigrants from
Mexico and Spanish monolingual speakers were biased to
inclusion in our sample because of our computer-based
data collection methods (QDS). Finally, our study is lim-
ited by the convenience sample framework used to recruit
IDUs into our study. However, the illegal status of several
SEPs in our study, coupled with the limited hours of SEP
operation, prevented us from using methods of random
sampling to recruit IDUs into our study.
Our data has taken some first steps at understanding how
and why the HIV prevention needs of Mexican American
IDUs may differ from White and African American IDUs,
though it is limited in its ability to tease out some of the
issues that deserve further consideration. More research
should be done to explore the role of neighborhoods and
communities in the lives of our participants, including how
far they may travel to access SEPs, drug treatment pro-
grams and other forms of health services, what level of
drug-related disclosure exists with families and friends, and
how injection practices are negotiated in social and sexual
networks. Exploring the intersection of cultural and struc-
tural factors in the lives of Mexican American IDUs may
offer new insights into how to reduce injection-related risk
behaviors, keep HIV seroprevalence low, and reduce bar-
riers to health care utilization.
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